Plasticell signs deal stem cell deal with JCR Pharmaceuticals

Published: 25-Feb-2014
Research & Development Pharmaceutical Cell & Gene Therapy

Will use its CombiCult stem cell technology to discover custom stem cell culture media


Plasticell, a UK biotechnology company specialising in stem cell differentiation, is to collaborate with JCR Pharmaceuticals of Japan, to discover custom stem cell culture media using its CombiCult stem cell technology.

Financial terms of the agreement have not been disclosed.

'Plasticell’s core capability to provide customers with optimised serum- and xeno-free GMP-grade stem cell differentiation or expansion protocols, which exclude patented factors and contain small molecule substitutes, together with the knowledge we have accumulated from a decade of differentiating all types of stem cells into a multitude of different cell types, has great potential to enhance the competitiveness of the Japanese stem cell effort,' said Dennis Saw, Chief Executive of Plasticell, which is based at Stevenage Bioscience Catalyst in Hertfordshire.

  • Companies:
  • Plasticell
See more

You may also like

Research & Development

Plasticell receives EU funding for neurodegenerative disease research

Read more
It is part of a €3.7 million consortium to be used to create and exploit advanced cellular models of neurological disorders like Parkinson´s, Huntington´s and Demyelination disease

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  4. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  5. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Plasticell receives EU funding for neurodegenerative disease research

It is part of a €3.7 million consortium to be used to create and exploit advanced cellular models of neurological disorders like Parkinson´s, Huntington´s and Demyelination disease
Research & Development

Plasticell wins military contract to develop regenerative medicines

The combinatorial cell culture technology will enable the biotech company to test very large numbers of cell culture variables in combinations, to discover optimal laboratory protocols for the manipulation of stem cells and other cell cultures
Media

Plasticell leads gene therapy manufacturing consortium

UK’s innovation agency provides funding to develop advanced technologies for the manufacturing of autologous ex vivo gene therapies
Research & Development

Regenerative medicine and the benefits of cell-based combinatorial screening technology

Although many technical challenges remain ahead, regenerative medicine has the potential to profoundly change the way in which we approach previously incurable diseases
Analysis

Plasticell and GSK collaborate to produce hematopoietic cells

Plasticell, a biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research 
Research & Development

Plasticell to produce red blood cell substitute from pluripotent stem cells

Combinatorial stem cell screening technology focuses on the early stages of stem cell differentiation
Research & Development

Plasticell collab on stem cell with Singapore universities

Genome editing tech will insert functional multi-transgene cassettes into specific loci of human stem cell lines
Subscribe now